These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33388281)

  • 1. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.
    Nakai Y; Takeuchi A; Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Minami K; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Morizane S; Kawasaki Y; Morooka D; Shimazui T; Yamamoto Y; Nakagomi H; Tomida R; Ito YM; Murai S; Kitamura H; Nishiyama H; Shinohara N;
    J Geriatr Oncol; 2021 Jun; 12(5):834-837. PubMed ID: 33388281
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of axitinib rechallenge in metastatic renal cell carcinoma.
    Suzuki K; Hara T; Terakawa T; Harada K; Fujisawa M
    Int J Urol; 2021 Jun; 28(6):702-703. PubMed ID: 33719092
    [No Abstract]   [Full Text] [Related]  

  • 3. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
    Umeyama Y; Shibasaki Y; Akaza H
    Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
    Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
    Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
    Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
    Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
    Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
    Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
    Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.
    Miyake H; Harada K; Ozono S; Fujisawa M
    Med Oncol; 2016 Aug; 33(8):95. PubMed ID: 27444960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib for the treatment of metastatic renal cell carcinoma.
    Parekh H; Griswold J; Rini B
    Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib controlled metastatic renal cell carcinoma for 5 years.
    Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S
    Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma.
    Godo S; Yoshida Y; Kawamorita N; Mitsuzuka K; Kawazoe Y; Fujita M; Kudo D; Nomura R; Shimokawa H; Kushimoto S
    Intern Med; 2018 Oct; 57(19):2895-2900. PubMed ID: 29780111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
    Miyake H; Harada KI; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
    Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
    Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib-induced acute pancreatitis: a case report.
    Péron J; Khenifer S; Potier V; Vitry T; Pasquet F; Rassat R; Pavic M
    Anticancer Drugs; 2014 Apr; 25(4):478-9. PubMed ID: 24398664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
    Rexer H; Bedke J
    Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.